10.1038/s41591-023-02704-x - First-line talazoparib with enzalutam...

This document has been corrected

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-023-02704-x

Published Online: 2023-12-04

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: A. Douglas Laird•Andre P. Fay•Arun A. Azad•Curtis Dunshee•Cynthia G. Healy•Dingwei Ye•Eric Voog•Fabian Zohren•Jae Young Joung•Jan Oldenburg•Joan Carles•Karim Fizazi•Neal D. Shore•Neeraj Agarwal•Nicola Di Santo•Nobuaki Matsubara•Peter C. C. Fong•Robert J. Jones•Stefanie Zschäbitz•Ugo De Giorgi•Xun Lin

This document has been corrected

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-023-02704-x

Published Online: 2023-12-04

Journal: Nature Medicine

NOW

2024-01-31•Correction

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-024-02835-9

* information provided by CrossRef

2024-01-31•Correction

10.1038/s41591-024-02835-9

* information provided by CrossRef

2023-12-04•Published

2024-01-31•Correction

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-024-02835-9

* information provided by CrossRef

This document has been corrected

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-023-02704-x

Published Online: 2023-12-04

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC